You do not have permission to access this chart.
Please Sign Up or Login

About:

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

75

Address:

F-star Therapeutics, Inc. Eddeva B920 Babraham Research Campus Cambridge CB22 3AT United Kingdom

Website:

http://www.f-star.com

Phone:

44 1223 497 400

Leave a comment

Your email address will not be published. Required fields are marked *